This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Exact Sciences' Colon Cancer Screening Trial

MADISON, Wisc. ( TheStreet) -- Exact Sciences (EXAS - Get Report) is enrolling patients in a large late-stage study of its colon cancer-screening test Cologuard to support a planned U.S. approval filing, the company announced Tuesday.

Cologuard is designed to detect altered genetic material in cells that are shed from the lining of the colon into stool from pre-cancerous and cancerous lesions. The Exact Sciences test can also detect blood in stool, which is another possible signal of colon cancer.

Patients benefit most when cancer is detected as early as possible, which is why Exact Sciences is engineering Cologuard to be especially sensitive to pre-cancerous lesions in the colon. Existing colon-cancer screening tests don't do a good job of picking up early-stage cancer.

The Cologuard phase III study began enrolling patients at the end of June and will recruit more than 10,000 patients between the ages of 50 and 84 who are at an average risk for colon cancer. All the patients will have stool collected for a Cologuard test and a commercially available fecal blood test. The patients will then undergo a standard colonoscopy. Doctors and patients will not be told the results of the Cologuard and fecal blood tests, which at the end of the study will be compared for accuracy against the results from the colonoscopy. Lesions suspected of being cancer will be confirmed by independent laboratory examination.

Exact Sciences says enrolling patients in the phase III colon cancer screening study will take between 12-15 months. Recruiting well over 10,000 patients may be necessary if the incidence of colon cancer detected in the study population is lower than predicted, said an Exact Sciences spokesperson.

Cologuard detected 85% of colon cancers and 64% of early pre-cancers, according to a validation study presented last year. The pre-cancer sensitivity, in particular, was especially strong, surpassing the company's goal of detecting 50% of pre-cancerous lesions.

Exact Sciences shares closed Monday at $8.80. The stock has more than doubled in value over the past year.

Colon cancer is the second leading cancer killer in the U.S, with about 142,000 new cases and 51,000 deaths each year, according to the National Cancer Institute. The American Cancer Society recommends that all Americans start getting tested for colon cancer at age 50. However, many patients do not comply fully with current screening recommendations. In fact, 60% of patients today are diagnosed with colorectal cancer in the late stages, primarily because of poor screening compliance.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
EXAS $7.02 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs